{"type":"trials","record":{"id":41421,"source_id":"clinicaltrials-gov","external_id":"NCT06765980","title":"A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","brief_summary":"The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).","overall_status":"Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Kriya Therapeutics, Inc.","enrollment":62,"countries":["United States","Canada","Israel","New Zealand"],"start_date":"2025-05-28","completion_date":"2027-12-15","last_update_date":"2026-08-10","source_url":"https://clinicaltrials.gov/study/NCT06765980","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"VISION","age_range":"55 Years to 80 Years","comparator":null,"organization":"Kriya Therapeutics, Inc.","interventions":["VV-14295"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical…","Rate of GA progression as assessed by optical coherence tomography (OCT) — 12 months","Rate of GA progression as assessed by fundus autofluorescence (FAF) — 3, 6, and 12 months","Rate of GA progression as assessed by OCT — 3, 6, and 12 months","Visual function preservation as assessed by best-corrected visual acuity (BCVA) — 3, 6, and 12 months","Visual function preservation as assessed by low luminance visual acuity (LLVA) — 3, 6, and 12 months","Visual function preservation as assessed by microperimetry — 3, 6, and 12 months","VV-14295 transgene product expression — 12 months","Immune response to VV-14295 — 12 months","Vector shedding profile of VV-14295 — 12 months","Safety of Everads Injector — 1 day post-dose"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Geographic Atrophy Secondary to Age-related Macular Degeneration","VV-14295"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06765980","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-05-28 to 2027-12-15","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.809Z","intervention":["VV-14295"],"participants":62,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical…","Rate of GA progression as assessed by optical coherence tomography (OCT) — 12 months","Rate of GA progression as assessed by fundus autofluorescence (FAF) — 3, 6, and 12 months","Rate of GA progression as assessed by OCT — 3, 6, and 12 months","Visual function preservation as assessed by best-corrected visual acuity (BCVA) — 3, 6, and 12 months","Visual function preservation as assessed by low luminance visual acuity (LLVA) — 3, 6, and 12 months","Visual function preservation as assessed by microperimetry — 3, 6, and 12 months","VV-14295 transgene product expression — 12 months","Immune response to VV-14295 — 12 months","Vector shedding profile of VV-14295 — 12 months","Safety of Everads Injector — 1 day post-dose"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41421","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}